Stock listing
Frankfurt:BXT BioNxt Solutions Inc Aktie
German listing (Frankfurt) of BioNxt Solutions Inc · home listing CSE:BNXT
Follow BioNxt Solutions Inc into a list and get an email when it puts out news.
Share price · FWB:BXT
€0.155 EUR -0.007 (-4.3%)
Close on Nov 6, 2026
- Day range
- €0.147 – €0.158 EURNov 6, 2026
- Volume
- 1,500 sharesNov 6, 2026
- Market cap
- €21.09M EURAt the close on Nov 6, 2026 · price × 136.1M shares outstanding
- 52-week range
- €0.147 – €0.532 EURLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- €4,510 EURMedian day 2,044 shares · 17 days with no trades · last 3 months, Aug 6, 2026 – Nov 6, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BNXT · Home | $0.26 CAD | -0.01 (-3.7%) | 11,000 | $0.26 | $0.26 | $0.26 | $0.27 | Close on Nov 6, 2026 |
| Xetra:BXT | €0.176 EUR | +0.012 (+7.3%) | 10,505 | €0.167 | €0.188 | €0.167 | €0.164 | Close on Nov 6, 2026 |
| OTC:BNXTF | $0.205 USD | 0.000 (0.0%) | — | $0.205 | $0.205 | $0.205 | $0.205 | Close on Nov 6, 2026 |
| Frankfurt:BXT | €0.155 EUR | -0.007 (-4.3%) | 1,500 | €0.158 | €0.158 | €0.147 | €0.162 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · FWB:BXT · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.155 | -0.007 | -4.3% | €0.158 | €0.158 | €0.147 | 1,500 | |
| €0.162 | +0.007 | +4.5% | €0.151 | €0.169 | €0.151 | 218,764 | |
| €0.155 | +0.006 | +4.0% | €0.161 | €0.163 | €0.155 | 17,214 | |
| €0.149 | -0.001 | -0.7% | €0.165 | €0.167 | €0.148 | 2,500 | |
| €0.150 | -0.005 | -3.2% | €0.172 | €0.209 | €0.150 | 10,000 | |
| €0.155 | -0.016 | -9.4% | €0.169 | €0.170 | €0.155 | 103,468 | |
| €0.171 | 0.000 | 0.0% | €0.171 | €0.220 | €0.169 | 369,662 | |
| €0.171 | -0.002 | -1.2% | €0.168 | €0.202 | €0.168 | 2,500 | |
| €0.173 | -0.001 | -0.6% | €0.165 | €0.215 | €0.165 | 0 | |
| €0.174 | +0.013 | +8.1% | €0.172 | €0.176 | €0.171 | 116,322 | |
| €0.161 | -0.011 | -6.4% | €0.161 | €0.161 | €0.161 | 0 | |
| €0.172 | +0.009 | +5.5% | €0.164 | €0.174 | €0.163 | 1,000 | |
| €0.163 | -0.010 | -5.8% | €0.172 | €0.172 | €0.163 | 0 | |
| €0.173 | +0.003 | +1.8% | €0.173 | €0.185 | €0.172 | 1,500 | |
| €0.170 | +0.001 | +0.6% | €0.186 | €0.220 | €0.168 | 0 | |
| €0.169 | -0.003 | -1.7% | €0.169 | €0.169 | €0.169 | 0 | |
| €0.172 | -0.008 | -4.4% | €0.172 | €0.172 | €0.172 | 0 | |
| €0.180 | -0.003 | -1.6% | €0.177 | €0.180 | €0.177 | 0 | |
| €0.183 | -0.009 | -4.7% | €0.188 | €0.188 | €0.174 | 129 | |
| €0.192 | +0.004 | +2.1% | €0.193 | €0.197 | €0.190 | 9,256 | |
| €0.188 | -0.003 | -1.6% | €0.189 | €0.234 | €0.188 | 63,505 | |
| €0.191 | -0.046 | -19.4% | €0.186 | €0.192 | €0.186 | 11,000 | |
| €0.237 | +0.035 | +17.3% | €0.237 | €0.238 | €0.210 | 25,350 | |
| €0.202 | +0.007 | +3.6% | €0.229 | €0.230 | €0.199 | 400 | |
| €0.195 | -0.016 | -7.6% | €0.211 | €0.213 | €0.194 | 24,925 | |
| €0.211 | -0.004 | -1.9% | €0.211 | €0.241 | €0.211 | 13,186 | |
| €0.215 | +0.002 | +0.9% | €0.215 | €0.241 | €0.215 | 1,659 | |
| €0.213 | -0.003 | -1.4% | €0.213 | €0.213 | €0.213 | 0 | |
| €0.216 | +0.001 | +0.5% | €0.237 | €0.240 | €0.216 | 7,100 | |
| €0.215 | -0.023 | -9.7% | €0.215 | €0.237 | €0.214 | 1,000 | |
| €0.238 | +0.017 | +7.7% | €0.237 | €0.240 | €0.237 | 3,000 | |
| €0.221 | +0.011 | +5.2% | €0.215 | €0.229 | €0.215 | 400 | |
| €0.210 | 0.000 | 0.0% | €0.210 | €0.238 | €0.209 | 2,500 | |
| €0.210 | -0.012 | -5.4% | €0.199 | €0.239 | €0.199 | 5,000 | |
| €0.222 | +0.023 | +11.6% | €0.201 | €0.273 | €0.199 | 270,000 | |
| €0.199 | -0.001 | -0.5% | €0.200 | €0.237 | €0.199 | 41,760 | |
| €0.200 | +0.007 | +3.6% | €0.190 | €0.238 | €0.189 | 23,800 | |
| €0.193 | -0.006 | -3.0% | €0.191 | €0.237 | €0.188 | 5,000 | |
| €0.199 | -0.010 | -4.8% | €0.191 | €0.203 | €0.191 | 0 | |
| €0.209 | +0.017 | +8.9% | €0.209 | €0.209 | €0.209 | 1,500 | |
| €0.192 | -0.019 | -9.0% | €0.192 | €0.239 | €0.192 | 63,428 | |
| €0.211 | +0.014 | +7.1% | €0.212 | €0.228 | €0.209 | 2,044 | |
| €0.197 | -0.004 | -2.0% | €0.197 | €0.241 | €0.197 | 10,800 | |
| €0.201 | -0.026 | -11.5% | €0.192 | €0.237 | €0.192 | 2,200 | |
| €0.227 | +0.013 | +6.1% | €0.237 | €0.239 | €0.226 | 1,200 | |
| €0.214 | -0.027 | -11.2% | €0.191 | €0.214 | €0.189 | 24,778 | |
| €0.241 | +0.043 | +21.7% | €0.199 | €0.242 | €0.199 | 8,470 | |
| €0.198 | +0.006 | +3.1% | €0.192 | €0.198 | €0.192 | 220 | |
| €0.192 | -0.025 | -11.5% | €0.221 | €0.222 | €0.191 | 1,500 | |
| €0.217 | 0.000 | 0.0% | €0.197 | €0.246 | €0.195 | 41,510 | |
| €0.217 | -0.010 | -4.4% | €0.217 | €0.222 | €0.215 | 24,778 | |
| €0.227 | +0.028 | +14.1% | €0.200 | €0.229 | €0.198 | 22,116 | |
| €0.199 | -0.012 | -5.7% | €0.202 | €0.226 | €0.198 | 11,000 | |
| €0.211 | +0.015 | +7.7% | €0.197 | €0.212 | €0.195 | 200 | |
| €0.196 | -0.016 | -7.5% | €0.196 | €0.196 | €0.196 | 0 | |
| €0.212 | +0.021 | +11.0% | €0.192 | €0.215 | €0.192 | 1,300 | |
| €0.191 | 0.000 | 0.0% | €0.191 | €0.191 | €0.191 | 0 | |
| €0.191 | +0.007 | +3.8% | €0.191 | €0.191 | €0.191 | 0 | |
| €0.184 | -0.005 | -2.6% | €0.184 | €0.184 | €0.184 | 0 | |
| €0.189 | -0.021 | -10.0% | €0.189 | €0.189 | €0.189 | 0 | |
| €0.210 | +0.027 | +14.8% | €0.191 | €0.214 | €0.191 | 34,000 | |
| €0.183 | -0.030 | -14.1% | €0.183 | €0.183 | €0.183 | 0 | |
| €0.213 | +0.004 | +1.9% | €0.185 | €0.216 | €0.185 | 0 | |
| €0.209 | +0.014 | +7.2% | €0.185 | €0.213 | €0.185 | 1,050 | |
| €0.195 | +0.012 | +6.6% | €0.184 | €0.214 | €0.183 | 0 | |
| €0.183 | -0.005 | -2.7% | €0.181 | €0.184 | €0.181 | 1,521 | |
| €0.188 | +0.008 | +4.4% | €0.181 | €0.188 | €0.179 | 3,000 |
- Ticker
- Frankfurt:BXT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 19, 2026
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Oct 19, 2026
Closed €0.17 (+0.6%) on Oct 19, 2026
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Sep 8, 2026
Closed €0.201 (-11.5%) on Sep 8, 2026
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Aug 21, 2026
Closed €0.196 (-7.5%) on Aug 24, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Aug 4, 2026
Closed €0.189 (+5.6%) on Aug 4, 2026
BioNxt Solutions Announces Option Grants
Jul 31, 2026
Closed €0.179 (-17.1%) on Aug 3, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
Jul 6, 2026
Closed €0.188 (-1.6%) on Jul 6, 2026
BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 23, 2026
Closed €0.207 (+11.9%) on Jun 24, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Jun 15, 2026
Closed €0.212 (0.0%) on Jun 15, 2026
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 12, 2026
Closed €0.212 (0.0%) on Jun 15, 2026
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
Jun 10, 2026
Closed €0.231 (-1.7%) on Jun 11, 2026
Financings
Private placement of units
Jun 23, 2026 · US$1.41M
Closed: C$2M raised · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of units
Jun 12, 2026 · US$1.43M
Announced: up to C$2M · C$0.33 a unit · 1 warrant at C$0.5 for 24 months
Use of proceeds: European research and development and operations, working capital and general corporate purposes
Private placement of convertible debenture units
Aug 8, 2025
Closed: C$1.25M raised · C$0.6 a unit · 1 warrant at C$0.75 for 24 months · Canaccord Genuity Corp. · free to trade Dec 9, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, and general working capital
Announced Jul 11, 2025 · Tranche closed Jul 25, 2025 · Closed Aug 8, 2025
Convertible debenture units
Mar 14, 2025
Closed: C$2.5M raised · C$0.5 a unit · 1 warrant at C$0.6 for 24 months · Canaccord Genuity Corp. · free to trade Jul 15, 2025
Dealers: Canaccord Genuity Corp. (finder)
Use of proceeds: Product development and commercialization, intellectual property filings, debt repayment, and general working capital
Decks
Investor Presentation (September 2026)
Investor deck · 27 slides · September 2026
Investor Presentation (November 2024)
Investor deck · 23 slides · November 2024
XPhyto Therapeutics — Investor Presentation (June 2021)
Investor deck · 16 slides · June 2021
BioNxt Solutions Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 66 in all · newest Oct 19, 2026 · oldest 2024
- Decks
- 3 decks · latest September 2026
Where BioNxt Solutions Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BNXT · Home listing | CSE | Canada | CAD |
| Xetra:BXT | Xetra | Germany | EUR |
| gettex:BXT | gettex | Germany | EUR |
| LS Exchange:A3D1K3 | LS Exchange | Germany | EUR |
| Tradegate:BXT | Tradegate | Germany | EUR |
| Lang & Schwarz:A3D1K3 | Lang & Schwarz | Germany | EUR |
| Cboe Canada:BNXT | Cboe Canada | Canada | CAD |
| OTC:BNXTF | OTC | United States | USD |
| Frankfurt:BXT · This page | Frankfurt | Germany | EUR |
| Dusseldorf:BXT | Dusseldorf | Germany | EUR |
| Hamburg:BXT | Hamburg | Germany | EUR |
| Munich:BXT | Munich | Germany | EUR |
| Stuttgart:BXT | Stuttgart | Germany | EUR |
| Hanover:BXT | Hanover | Germany | EUR |
Log in to ask 6ix AI your own questions about BioNxt Solutions Inc.